The study found that a combination of Atezolizumab and bevacizumab medicines is safe and effective in treating patients with liver cancer in real-world settings.
Hyderabad: Good news for liver cancer sufferers in Hyderabad! A combination of medications used in the treatment of liver cancer patients has proven to be particularly efficient in disease management and tumor resolution, according to a peer-reviewed study published on Wednesday by the Hyderabad-based Asian Institute of Gastroenterology (AIG).
The study’s findings, which included liver cancer patients from Hyderabad and Jaipur and were published in the Journal of Clinical and Experimental Hepatology (July-August, 2023), show that a combination of Atezolizumab and bevacizumab drugs is safe and effective in treating liver cancer patients in real-world settings.
There have been no trials from India that have reported the safety and efficacy of this combination medicine in real-world settings where the majority of the patients in the study were in an advanced stage of liver cancer.
Between November 1, 2020, and July 1, 2022, patients with liver cancer at AIG Hospitals in Hyderabad and Mahatma Gandhi Hospitals in Jaipur received at least three cycles of Atezolizumab-bevacizumab medication treatment. The patients had liver cancer as a result of a range of diseases, including alcohol usage (cirrhosis), non-alcoholic hepatitis, and Hepatitis B and C.
The main finding of the trial was that the illness Control Rate, which is the proportion of persons who improved (partial response) or did not worsen (stable illness) after taking this medication, was 66.1 percent. The study’s overall positive response (ORR), also known as the Objective Response Rare, was 38.7 percent, showing that the patients reacted favorably to the medication.
According to the AIG study, 25.8 percent of patients in the trial group saw partial tumor remission, while 12.9 percent experienced complete tumor resolution.
The combination of locoregional therapy (minimally invasive operations) with the Atezolizumab-bevacizumab medications is a future method, according to the researchers, to achieve a full response, i.e. the absence of all detectable cancer after treatment completion, and to prolong longevity.
According to the study, patients who had Y90-TARE (method to target the tumor without destroying healthy tissue of the liver tumor) followed by Atezolizumab-bevacizumab treatment had a 100 percent overall favorable response.